Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry
Executive Summary
Published results from the Xarelto (rivaroxaban) pivotal trial in atrial fibrillation throw more light on the efficacy and safety concerns likely to be aired at a Sept. 8 FDA advisory committee review of the Bayer/Johnson & Johnson anticoagulant.
You may also be interested in...
Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?
Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) may be the first of the new anticoagulants to show a significant mortality benefit in the atrial fibrillation population, but it remains to be seen whether this advantage will withstand FDA’s regulatory scrutiny.
Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?
Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) may be the first of the new anticoagulants to show a significant mortality benefit in the atrial fibrillation population, but it remains to be seen whether this advantage will withstand FDA’s regulatory scrutiny.
Bristol/Pfizer's Apixaban Shows Mortality Benefit In ARISTOTLE, But Is It Enough To Supplant Warfarin?
New England Journal of Medicine editorial says cost-effectiveness data and head-to-head studies on new oral anticoagulants are needed to move prescribing away from warfarin for atrial fibrillation patients.